HOME >> BIOLOGY >> NEWS
Delivering the fruits of biotechnology to the developing world: Institute for Global Health sponsors global health forum, February 18-21

Leaders from governments, biotechnology companies, and multi-lateral agencies from around the world will gather in Carmel Valley, CA, February 18-21 to study how best to promote development of drugs and vaccines for the world's poorest countries. This Global Health Forum: "Creating Global Markets for Orphan Drugs & Vaccines: A Challenge for Public/Private Partnership," will be sponsored by the Institute for Global Health, of the University of California, San Francisco, and UC Berkeley.

Although the forum is closed to the press and the public, its participants will publish a set of conclusions and recommendations for action. They will discuss these recommendations at a press briefing in San Francisco, Tuesday, February 22.

As the biotechnology and vaccine industries have blossomed in recent decades, they have focused predominantly on diseases affecting the world's richest countries. Diseases that plague poor countries, such as malaria and sleeping sickness, have been largely ignored, said Dr. Richard Feachem, PhD, DSc(Med), founding director of the Institute for Global Health, and a professor of international health at UCSF and UC Berkeley.

"Modern biomedical science and biotechnology are beginning to deliver fantastically powerful new drugs and new vaccines. We must find ways to bring the fruits of medical science to all people in the world who could benefit from them. If we fail, the consequences will be catastrophic," he said.

Without a more concerted effort, the epidemics developing countries are now facing will reach catastrophic proportions, Feachem said. "In a few years, malaria will be untreatable, and HIV will have caused devastation in Asia as it has already in Africa," he said. Malaria parasites are quickly becoming resistant and there are no new drugs in the development pipeline, and HIV vaccines that low income countries can afford and use are still years away, he

Several public/private partnerships targeting individual diseas
'"/>

Contact: Kevin Boyd
kboyd@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
6-Feb-2000


Page: 1 2 3

Related biology news :

1. More people are getting sick from eating fresh fruits
2. Middle-aged women who consume many fruits and vegetables are at much lower risk of cardiovascular disease
3. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
4. UK biotechnology business plan competition now open to students in the US and Canada
5. Plants for the future: A European vision for plant biotechnology towards 2025
6. University of Pittsburgh Medical Center acquires biotechnology firm Rheogene Inc.
7. Poll: NY residents split on biotechnology in food and agriculture
8. First company founded on UCF biotechnology formed
9. NASA biotechnology activities enhancing quality of life
10. Genetic engineering accelerates the impact of biotechnology on chemical production
11. Symposium to focus on ethical issues in biotechnology

Post Your Comments:
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
(Date:3/4/2015)... -- The UPMC Center for Health Security today announced ... Leaders in Biosecurity Initiative (ELBI). As part of our ... biosecurity, UPMC has selected 28 US and international emerging ... including biological science, medicine, policy, the military, think tanks ... vision and support of the Defense Threat Reduction Agency ...
(Date:3/4/2015)... /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today ... research program with Emerald Logic, a leader ... Technology (FACET), Emerald Logic analyzed Resverlogix,s complete ... each of 798 patients who participated in ... SUSTAIN and ASSURE. The objective of this ...
(Date:3/4/2015)... , March 4, 2015 Vegalab announced the ... August of last year. As part of the acquisition, ... Koo continuing his role as CEO for the ... Vegalab S.A., will work alongside Koo and oversee developments ... http://photos.prnewswire.com/prnh/20150303/179218 Koo founded Ecowin ...
(Date:3/3/2015)... SAN DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - ... company developing new therapeutics and molecular diagnostics that target ... for the quarter and seventh-month period ended December 31, ... changed its fiscal year end from May 31 to ... periods we are reporting today are for the quarter ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
Cached News: